Equity · Healthcare
RAPP
NASDAQRapport Therapeutics (RAPP)
The line runs 49 USD on 24 August through 23.16 USD on 20 November, on a scale from 20 to 60. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.4B USD
- EPS, diluted, year to Dec 2025
- −2.86 USD
- 52-week range
- 22.10 USD – 52 USD
- Avg volume
- 65.9K
- Mentions, 30 days
- 7
- Net sentiment
- +0.10
as of Nov 20, 2026
Have Rapport Therapeutics (RAPP) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Rapport Therapeutics insiders reported 9 open-market sales and 7 purchases (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 28 Oct 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 28 Oct 2026 | HEALY JAMESDirector | Buy | 969,480 | 20.4M USD |
| 23 Oct 2026 | Sanchez RamiroDirector | Buy | 3,600 | 98K USD |
| 22 Oct 2026 | MARAGANORE JOHNDirector | Buy | 9,411 | 249K USD |
| 22 Oct 2026 | PAUL STEVEN MDirector | Buy | 35,714 | 974K USD |
| 22 Oct 2026 | Young Wendy B.Director | Buy | 3,789 | 100K USD |
| 22 Oct 2026 | Silva Paul MDirector | Buy | 3,680 | 100K USD |
| 21 Oct 2026 | Ignelzi Troy A.Chief Financial Officer | Buy | 5,500 | 144K USD |
| 21 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sell | 2,210 | 64K USD |
| 07 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sell | 1,147 | 35K USD |
| 06 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sell | 3,375 | 108K USD |
| 30 Sep 2026 | Gault CherylChief Operating Officer | Sell | 10,000 | 332K USD |
| 23 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sell | 2,210 | 87K USD |
| Bought | 7 open-market purchases | 1,031,174 | $22.02M | |
| Sold | 9 open-market sales | 96,233 | $4.47M |
Showing the 12 most recent of 16 open-market trades in this window. The figures above count all of them.
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Oct 2026 | Third Rock Ventures V, L.P.Director | Award | 1,428,571 | 30.0M USD |
Which funds hold Rapport Therapeutics (RAPP)?
6 of the 45 institutional funds we track reported a Rapport Therapeutics position for the quarter ended 30 Sep 2026 — a combined 61.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 1,547,090 | 52.0M USD | |
| D. E. Shaw & Co. | Trimmed | 114,318 | 3.8M USD | −46.8% |
| Millennium Management | Trimmed | 68,118 | 2.3M USD | −56.0% |
| Two Sigma Investments | Added | 65,796 | 2.2M USD | +168.9% |
| AQR Capital Management | Held (±25%) | 27,833 | 935K USD | +5.2% |
| Citadel Advisors | Trimmed | 15,289 | 514K USD | −81.5% |
What has been filed or recorded for Rapport Therapeutics (RAPP)?
The filings we hold for Rapport Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 156,377 shares | 3.5M USD notional · 0.264% of shares out |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 559 shares | 14K USD notional · 0.001% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 31 shares | 910 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.84 USD | |
| 30 Sep 2026 | Financials | Total assets | 418.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 391.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.19 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.42 USD | Revenue $20M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.86 USD | |
| 31 Dec 2025 | Financials | Net income | −111.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.86 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.71 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.75 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.68 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −3.78 USD |
What is Reddit saying about Rapport Therapeutics (RAPP)?
Reddit mentioned RAPP 7 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 71% read bullish, 0% bearish and 29% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Rapport Therapeutics (RAPP) compare with its price?
Share ↗
Which subreddits are talking about Rapport Therapeutics (RAPP)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/stocks | 100% | 7 | +0.10 |
What do people ask about Rapport Therapeutics (RAPP)?
What did Rapport Therapeutics shares close at?23.16
Rapport Therapeutics closed at 23.16 USD on 20 Nov 2026, down 1.95% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Rapport Therapeutics’ market cap?1.4B
Rapport Therapeutics is worth 1.4B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Rapport Therapeutics insiders bought or sold shares recently?9 sales
In the 90 days to 22 Nov 2026, Rapport Therapeutics insiders reported 9 open-market sales and 7 purchases (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Rapport Therapeutics?6 of 45
6 of the 45 funds we track reported a Rapport Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, D. E. Shaw & Co. and Millennium Management. See Funds
When did Rapport Therapeutics last report earnings?−0.84
Rapport Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.84 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Rapport Therapeutics?0 mentions
Rapport Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 7 times over the trailing 30 days. Of the 7 mentions scored for sentiment, 71% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words